Navigation Links
ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease
Date:2/26/2009

PARIS, February 26 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) is pleased to announce that clinical testing of EHT 0202, its lead compound in Alzheimer's disease, is progressing well. Patient enrolment for the Phase IIa trial assessing EHT 0202 in patients with Alzheimer's disease is completed.

"The successful completion of patient enrolment for the Phase IIa represents an important milestone in the development of EHT 0202, and provides a clear timeline for the release of results," stated Dr. Loic Maurel, President of the Management Board of ExonHit Therapeutics. "Our strategy is to bring EHT 0202 up to the end of the ongoing study and then to look for a partner to move EHT 0202 through further clinical development. We have already met with several pharmaceutical companies that are looking forward to the Phase IIa results."

The trial is conducted under the supervision of Professor Bruno Vellas, Head of Alzheimer's Disease Clinical Research Center and Gerontopole, Toulouse University Hospital, France.

"EHT 0202 has an original mechanism of action: it stimulates the alpha-secretase pathway. If the neuroprotective and symptomatic effects of EHT 0202 demonstrated in animal models are confirmed in humans, it could change the treatment paradigm for Alzheimer's disease," stated Professor Vellas. "Current available drugs are symptomatic only and their clinical efficacy is limited over time, after which the evolution of the degenerative process starts progressing again. EHT 0202 is an interesting approach to potentially slow the evolution of the disease."

The Phase IIa trial is a multicenter, randomized, double-blind, placebo-controlled study primarily investigating the safety and tolerability of EHT 0202 in approximately 150 patients with Alzheimer's disease. The effect of two different doses of EHT 0202 as adjunctive therapy to an acetylcholinesterase inhibitor
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
2. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
3. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
4. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
5. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
6. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
7. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
8. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
11. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...O,Nov.24/PRNewswire-FirstCall/--Orexigen®Ther...panyfocusedonthetreatmentofobesity,todayannouncedt...ompany,sBoardofDirectorsgrantedaninducementstockop...lassen,M.D.,itsnewlyappointedHeadoftheGlobalContra...entivestockoptiontotheextentpermittedbylawandhasan...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--KeryxBiopharmaceuti...ur,theCompany,sChiefExecutiveOfficer,isscheduledto...encebeingheldinNewYorkCity. ,, Mr.Bentsur,spres...10:30AMETandwillbeaccessiblefromtheInvestorInforma...eryx.com .Anarchivedversionofthewebcastwillbeavail...
(Date:11/23/2009)...ATI,Nov.23/PRNewswire-FirstCall/--HealthWarehouse....derpharmacy,todayannounceditsfinancialresultsforth...tedquarterlyrevenueof$1,006,721,drivenbyheavygrowt...insincreased13.0%year-over-yearto34.6%andthenetlos...299forthethreemonthsendedSeptember30,2008. ,, "...
Breaking Medicine Technology:Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 2Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 3Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 2HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 3blue sky scrubs adds Caribbean Blue Scrubs 61357 1blue sky scrubs adds Caribbean Blue Scrubs 61357 2TET Systems and Novo Nordisk sign license agreement 10723 1TET Systems and Novo Nordisk sign license agreement 10723 2Pierre S Freeman Adds Book AMORC Unmasked 21 To his Arsenal of Whistleblower Weapons Aimed at Rosicrucian Order 61353 1Pierre S Freeman Adds Book AMORC Unmasked 21 To his Arsenal of Whistleblower Weapons Aimed at Rosicrucian Order 61353 2Pierre S Freeman Adds Book AMORC Unmasked 21 To his Arsenal of Whistleblower Weapons Aimed at Rosicrucian Order 61353 3
... - New Study Demonstrated the Clinical Potential o...s, Which Were as Effective as,Avastin(R) in Animal...Newswire-FirstCall/ --,Peregrine Pharmaceuticals, ...developing targeted monoclonal antibodies,for the ...n, today,reported that data from multiple studies ...
... LOS ANGELES--(BUSINESS WIRE)--Apr 23, 2007 - CytR...he RNA interference (RNAi),delivery technology exc..., RXi Pharmaceuticals Corporation (RXi), has been,... scientific,journal ACS Chemical Biology. The tech... Advisory Board member and University of,Massachus...
Other Medicine Technology:Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 2Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 3Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 4Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 7CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4
(Date:11/24/2009)...TheAmericanSocietyofEchocardiography(ASE)hasreleas...0CMSPhysicianFeeSchedule(PFS)onpatientsandpractice...ndtechnicianssurveyed,87percentsaidthenewfeeschedu...ducestafforshutdowntheirpracticecompletely--ultima...ltrasound)andothervitalservices. ,, Onecardiacs...
(Date:11/24/2009)...tCall/--RegeneronPharmaceuticals,Inc.(Nasdaq: REGN...ffrayHealthcareConferenceonTuesday,December1,2009....hesessionmaybeaccessedthroughtheCompany,swebsite, ...chivedversionofthepresentationwillbeavailableafter...ormationaboutRegeneronandrecentnewsreleasesareavai...
(Date:11/24/2009)...eezing, study finds , , TUESDAY, Nov. 24...affic pollution and indoor endotoxin are at increa...in -- a component of bacteria believed to trigger ..., University of Cincinnati College of Medicine ...rning sign of asthma and other lung conditions) in...
(Date:11/24/2009)... likely to become disabled, study finds , ...hildren may slow the progression of multiple scler...hers followed 330 women who had experienced their ..., Women who had given birth to at least one chil...progress to a stage in which they needed walking a...
(Date:11/24/2009)...diaMediTechCompany,aleading,pharmaceuticalR&Do...thatthecompanyreceivedtheRedHerringAsiaTop100Enter...hnologycompaniesintheAsiaPacific,region. , Re...rvarious,regions,suchasNorthAmerica,Europe,andAsia...ttherequirementsofcutting-edgetechnology,andoutsta...
Breaking Medicine News(10 mins):Health News:Lives Compromised and Patient Access Limited with New Cuts to Medicare 2Health News:Traffic, Dust Linked to Asthma in Kids 2Health News:Childbirth May Slow Progression of Multiple Sclerosis 2Health News:Childbirth May Slow Progression of Multiple Sclerosis 3
...n-anemic women between ages 18 and 55 with unexpla...d to women with low ferritin, a protein that store...leen. Researchers from the University of Lausan...decreased by 29 percent in the iron group compared...
...ntrol and Prevention has reported a global fall in...s a contagious disease and is the fifth leading ca...is has largely been possible due to improved vacci...t in the developing countries.// According to repo...
...ases Monday, the smallest number of new cases sinc...ports on the spread of the SARS epidemic last mont...in Beijing and Inner Mongolia, bringing China's de...w death and one// infection Monday. The epidemic h...
...ne that might be responsible for asthma. Scientist...g of the disease, hence leading to better treatme...ant effect on a person's susceptibility to asthma...some that was known to contain an asthma-related g...
...are often caused by bacteria and are frequently tr...Fluoroquinolones have been recommended empirical t... indicates that Ciprofloxacin has high activity ag...ly treatment option for these difficult-to treat i...
...ic illness could be triggered by abortion. However...ctic from the anti-abortion movement. Researchers ...ancies were more likely to be hospitalised for psy...who had an abortion were nearly three times more l...
Other Medicine News:
Roche COMPACT 3 Blood Gas Analyzer
GEM® Premier™ 3000 with iQM™
ABL800 FLEX Blood Gas Analyzer
AGIT1006 Agitator
Medicine Products: